Cover Image

HARDBACK
$52.95



View/Hide Left Panel

Age Groups

Populations

Incidence Rates (per 100,000)

% Distribution of Cases

Cases

MORTALITY ASSOCIATED WITH HSV CNS INFECTION

<1

3,963,000

0.00

0.0000

 

1–4

16,219,000

0.00

0.0000

5–14

38,056,000

0.39

0.2222

150

15–24

36,263,000

0.00

0.0000

 

25–34

41,670,000

0.00

0.0000

35–44

42,149,000

0.00

0.0000

45–54

30,224,000

0.43

0.1944

131

55–64

21,241,000

0.62

0.1944

131

65–74

18,964,000

0.69

0.1944

131

75–84

11,088,000

1.18

0.1944

131

85+

3,598,000

0.00

0.0000

 

Total

263,435,000

0.26

1.0000

675

INCIDENCE OF GENITAL HSV INFECTION

<1

3,963,000

0.00

0.0000

 

1–4

16,219,000

0.00

0.0000

5–14

38,056,000

0.00

0.0000

15–24

36,263,000

275.76

0.3333

100,000

25–34

41,670,000

479.96

0.6667

200,000

35–44

42,149,000

0.00

0.0000

 

45–54

30,224,000

0.00

0.0000

55–64

21,241,000

0.00

0.0000

65–74

18,964,000

0.00

0.0000

75–84

11,088,000

0.00

0.0000

85+

3,598,000

0.00

0.0000

Total

263,435,000

113.88

1.0000

300,000

adults who experience the acute CNS disease. This chronic condition is assumed to be associated with an HUI of .19 for the duration of the person’s life.

Genital Infections

For the purposes of the calculations in this report, it was assumed that 100% of genital HSV infections are associated with a 2-week period at an HUI of .81 (genital lesions, fever, pain). It is assumed that 90% of infections lead to 10 years of minor recurrences; 10% of infections are associated with 5 years of more severe recurrences.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement